Diagnosing IBD by Evaluating Epigenetic Markers in Blood
|
By Gerald M. Slutzky, PhD Posted on 07 Dec 2016 |
|
Image: A micrograph showing inflammation of the large bowel in a case of inflammatory bowel disease (Photo courtesy of Wikimedia Commons).
Epigenetic screening of blood samples has been proposed as a new approach to diagnosing patients with inflammatory bowel diseases (IBD).
Symptoms are similar in Crohn's disease, ulcerative colitis, and other inflammatory bowel conditions, which makes it difficult for doctors to diagnose which of the illnesses a patient has.
In an effort to develop better diagnostic tools for IBD, investigators at the University of Edinburgh (United Kingdom) used Illumina (San Diego, CA, USA) instruments and microarray technology to determine differentially methylated sites in whole blood and in immunomagnetically separated leucocytes (CD4+ and CD8+ lymphocytes and CD14+ monocytes) from 240 newly-diagnosed IBD cases and 190 controls.
The investigators reported that they had identified differentially methylated positions (DMPs) and regions (DMRs) in whole-blood DNA samples from 240 newly diagnosed IBD cases (121 Crohn's disease and 119 ulcerative colitis) and 191 controls. Technical validation and detailed characterization of DMRs was performed in a small cohort of six cases (three Crohn's disease and three ulcerative colitis) and three controls using whole-genome bisulphite sequencing. Independent validation of methylation results was performed using bisulphite pyrosequencing in a further cohort of 240 patients with established IBD and 98 controls.
Senior author Dr. Jack Satsangi, professor of gastroenterology at the University of Edinburgh, said, "Our findings bring fresh insights to the underlying causes of inflammatory bowel diseases, which could eventually lead to new treatments. Characterizing epigenetic signatures in the DNA of patients could help us to devise better tests for diagnosing these diseases, so that patients can be given the best possible care."
The study was published in the November 25, 2016, online edition of the journal Nature Communications.
Related Links:
University of Edinburgh
Illumina
.jpg)
Symptoms are similar in Crohn's disease, ulcerative colitis, and other inflammatory bowel conditions, which makes it difficult for doctors to diagnose which of the illnesses a patient has.
In an effort to develop better diagnostic tools for IBD, investigators at the University of Edinburgh (United Kingdom) used Illumina (San Diego, CA, USA) instruments and microarray technology to determine differentially methylated sites in whole blood and in immunomagnetically separated leucocytes (CD4+ and CD8+ lymphocytes and CD14+ monocytes) from 240 newly-diagnosed IBD cases and 190 controls.
The investigators reported that they had identified differentially methylated positions (DMPs) and regions (DMRs) in whole-blood DNA samples from 240 newly diagnosed IBD cases (121 Crohn's disease and 119 ulcerative colitis) and 191 controls. Technical validation and detailed characterization of DMRs was performed in a small cohort of six cases (three Crohn's disease and three ulcerative colitis) and three controls using whole-genome bisulphite sequencing. Independent validation of methylation results was performed using bisulphite pyrosequencing in a further cohort of 240 patients with established IBD and 98 controls.
Senior author Dr. Jack Satsangi, professor of gastroenterology at the University of Edinburgh, said, "Our findings bring fresh insights to the underlying causes of inflammatory bowel diseases, which could eventually lead to new treatments. Characterizing epigenetic signatures in the DNA of patients could help us to devise better tests for diagnosing these diseases, so that patients can be given the best possible care."
The study was published in the November 25, 2016, online edition of the journal Nature Communications.
Related Links:
University of Edinburgh
Illumina
Gold Member
Chagas Disease Test
CHAGAS Cassette
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
Latest Pathology News
- New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
- "Metal Detector" Algorithm Hunts Down Vulnerable Tumors
- Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
- Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
- AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
- AI Model Predicts Patient Response to Bladder Cancer Treatment
- New Laser-Based Method to Accelerate Cancer Diagnosis
- New AI Model Predicts Gene Variants’ Effects on Specific Diseases
- Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
- Pre-Analytical Conditions Influence Cell-Free MicroRNA Stability in Blood Plasma Samples
- 3D Cell Culture System Could Revolutionize Cancer Diagnostics
- Painless Technique Measures Glucose Concentrations in Solution and Tissue Via Sound Waves
- Skin-Based Test to Improve Diagnosis of Rare, Debilitating Neurodegenerative Disease
- Serum Uromodulin Could Indicate Acute Kidney Injury in COVID-19 Patients
- AI Model Reveals True Biological Age From Five Drops of Blood
- First-Of-Its-Kind AI Tool Visualizes Cell’s ‘Social Network’ To Treat Cancer
Channels
Clinical Chemistry
view channel
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Molecular Diagnostics
view channel
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read more
Blood Test Could Identify Patients at Risk for Severe Scleroderma
Systemic sclerosis, also known as scleroderma, causes the hardening of the skin and connective tissues. In many cases, the disease can also damage vital organs, including the heart, kidneys, lungs, and... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Technology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read more
Industry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
